Allianz Asset Management Gmb H Corbus Pharmaceuticals Holdings, Inc. Transaction History

Allianz Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$4.29 - $5.64 $247,477 - $325,354	-57,687 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$4.87 - $7.08 $404,677 - $588,319	-83,096 Reduced 59.02%	57,687 $281,000
Q2 2019 Aug 08, 2019	SELL	$6.6 - $7.8 $11,305 - $13,361	-1,713 Reduced 1.2%	140,783 $976,000
Q1 2019 May 13, 2019	SELL	$5.76 - $8.95 $4,112 - $6,390	-714 Reduced 0.5%	142,496 $990,000
Q4 2018 Feb 14, 2019	SELL	$5.26 - $7.97 $29,761 - $45,094	-5,658 Reduced 3.8%	143,210 $836,000
Q3 2018 Nov 13, 2018	BUY	$4.65 - $7.95 $56,106 - $95,924	12,066 Added 8.82%	148,868 $1.12 Million
Q2 2018 Aug 13, 2018	SELL	$5.05 - $6.8 $4,151 - $5,589	-822 Reduced 0.6%	136,802 $691,000
Q1 2018 May 14, 2018	BUY	$5.6 - $9.25 $105,156 - $173,696	18,778 Added 15.8%	137,624 $840,000
Q4 2017 Feb 13, 2018	SELL	$6.6 - $7.78 $10,612 - $12,510	-1,608 Reduced 1.33%	118,846 $844,000
Q3 2017 Nov 13, 2017	SELL	$5.75 - $7.75 $1,529 - $2,061	-266 Reduced 0.22%	120,454 $861,000
Q2 2017 Aug 14, 2017	BUY	N/A	29,040 Added 31.68%	120,720 $761,000
Q1 2017 Apr 17, 2019	BUY	N/A	91,680	91,680 $756,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.19B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.